Analyst Activity – Ascendiant Capital Markets Initiates Coverage On Novus Therapeutics (NASDAQ:NVUS) With a Buy

Analyst Ratings For Novus Therapeutics (NASDAQ:NVUS)

Today, Ascendiant Capital Markets initiated coverage on Novus Therapeutics (NASDAQ:NVUS) with a Buy with a price target of $7.00.

Some recent analyst ratings include

  • 2/13/2018-Ascendiant Capital Markets initiated coverage with a Buy rating.
  • 8/24/2016-BMO Capital Markets Reiterated Rating of Market Perform.
  • 8/10/2016-William Blair Reiterated Rating of Neutral.
  • 7/28/2016-Bank of America was Downgraded by analysts at Bank of America from a “Neutral ” rating to a ” Underperform” rating.
  • 7/26/2016-Stifel Nicolaus was Downgraded by analysts at Stifel Nicolaus from a “Buy ” rating to a ” Hold” rating.
  • 7/26/2016-Janney Montgomery Scott was Downgraded by analysts at Janney Montgomery Scott from a “Buy ” rating to a ” Neutral” rating.
  • 7/26/2016-Wells Fargo & Co was Downgraded by analysts at Wells Fargo & Co from a “Outperform ” rating to a ” Market Perform” rating.

Recent Insider Trading Activity For Novus Therapeutics (NASDAQ:NVUS)
Novus Therapeutics (NASDAQ:NVUS) has insider ownership of 5.20% and institutional ownership of 40.76%.

  • On 5/10/2017 Catherine C. Turkel, Insider, bought 11,111 with an average share price of $9.99 per share and the total transaction amounting to $110,998.89.
  • On 5/10/2017 Gregory J. Flesher, CEO, bought 58,959 with an average share price of $9.99 per share and the total transaction amounting to $589,000.41.
  • On 3/15/2016 Stephen Jr. Buckley, Director, bought 8,000 with an average share price of $5.74 per share and the total transaction amounting to $45,920.00.
  • On 11/11/2015 Stephen Jr. Buckley, Director, bought 3,000 with an average share price of $11.25 per share and the total transaction amounting to $33,750.00.
  • On 9/21/2015 John S. Mcbride, COO, sold 13,500 with an average share price of $14.01 per share and the total transaction amounting to $189,135.00.
  • On 9/8/2015 Lee Kalowski, CFO, sold 4,668 with an average share price of $13.13 per share and the total transaction amounting to $61,290.84.
  • On 9/2/2015 Lee Kalowski, CFO, sold 2,158 with an average share price of $12.96 per share and the total transaction amounting to $27,967.68.

Recent Trading Activity for Novus Therapeutics (NASDAQ:NVUS)
Shares of Novus Therapeutics closed the previous trading session at 3.20 up +0.05 1.59% with 3.130000114440918 shares trading hands.

An ad to help with our costs